Boston Scientific Corp.

  • Market Cap: Large Cap
  • Industry: Retailing
  • ISIN: US1011371077
USD
97.72
-0.85 (-0.86%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Boston Scientific Corp.
Cencora, Inc.
Sally Beauty Holdings, Inc.
Henry Schein, Inc.
McKesson Corp.
Patterson Cos., Inc.
Cardinal Health, Inc.
Herbalife Ltd.
Myomo, Inc.
BIMI International Medical, Inc.
Jowell Global Ltd.
Why is Boston Scientific Corp. ?
1
Healthy long term growth as Net Sales has grown by an annual rate of 12.73%
  • OPERATING CASH FLOW(Y) Highest at USD 4,285 MM
  • ROCE(HY) Highest at 11.71%
  • NET SALES(Q) Highest at USD 5,061 MM
stock-recommendationReal-Time Research Report
Verdict Report
How much should you buy?
  1. Overall Portfolio exposure to Boston Scientific Corp. should be less than 10%
  2. Overall Portfolio exposure to Retailing should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Retailing)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Boston Scientific Corp. for you?

Low Risk, High Return

Absolute
Risk Adjusted
Volatility
Boston Scientific Corp.
7.57%
1.16
23.63%
S&P 500
13.22%
0.64
20.20%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
12.73%
EBIT Growth (5y)
26.06%
EBIT to Interest (avg)
5.69
Debt to EBITDA (avg)
2.84
Net Debt to Equity (avg)
0.47
Sales to Capital Employed (avg)
0.50
Tax Ratio
18.32%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
93.61%
ROCE (avg)
6.99%
ROE (avg)
7.79%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
86
Industry P/E
Price to Book Value
8.01
EV to EBIT
64.79
EV to EBITDA
44.86
EV to Capital Employed
5.78
EV to Sales
10.73
PEG Ratio
6.37
Dividend Yield
5843.20%
ROCE (Latest)
8.92%
ROE (Latest)
9.28%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

20What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD 4,285 MM

ROCE(HY)

Highest at 11.71%

NET SALES(Q)

Highest at USD 5,061 MM

RAW MATERIAL COST(Y)

Fallen by -0.08% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 7.09 times

OPERATING PROFIT(Q)

Highest at USD 1,258 MM

PRE-TAX PROFIT(Q)

Highest at USD 1,197 MM

NET PROFIT(Q)

Highest at USD 1,013.28 MM

EPS(Q)

Highest at USD 0.53

-5What is not working for the Company
INTEREST(Q)

At USD 99 MM has Grown at 13.79%

DEBT-EQUITY RATIO (HY)

Highest at 50.78 %

Here's what is working for Boston Scientific Corp.
Operating Cash Flow
Highest at USD 4,285 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales
Highest at USD 5,061 MM and Grown
In each period in the last five periods
MOJO Watch
Near term sales trend is very positive

Net Sales (USD MM)

Pre-Tax Profit
At USD 1,197 MM has Grown at 85.29%
over average net sales of the previous four periods of USD 646 MM
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit
At USD 1,013.28 MM has Grown at 95.73%
over average net sales of the previous four periods of USD 517.69 MM
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (USD MM)

Operating Profit
Highest at USD 1,258 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit
Highest at USD 1,197 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD 1,013.28 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

EPS
Highest at USD 0.53
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Debtors Turnover Ratio
Highest at 7.09 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by -0.08% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Boston Scientific Corp.
Interest
At USD 99 MM has Grown at 13.79%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Debt-Equity Ratio
Highest at 50.78 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio